Bank of America’s Aimmune Therapeutics AIMT Stock Holding History

Bank of America’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-30,000	Closed	-$628K	–	7604
2019 Q3	$628K	Buy	+30,000	New	+$612K	﹤0.01%	4919
2017 Q4	–	Sell	-10,900	Closed	-$270K	–	7376
2017 Q3	$270K	Buy	+10,900	New	+$235K	﹤0.01%	5254

Bank of America's AIMT Position: Q4 2020 in Review

Bank of America sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 168,202 shares — an estimated $5.79M sold.

Bank of America first reported a position in AIMT in Q3 2015 and held it in 21 quarters. The position peaked at $14.7M in Q4 2019. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Bank of America reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Bank of America sold 168,202 Aimmune Therapeutics shares in Q4 2020, an estimated $5.79M.
Bank of America first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 21 quarters.
Bank of America's Aimmune Therapeutics position peaked at $14.7M in Q4 2019.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Bank of America's 13F filing for Q4 2020, filed 10 Feb 2021.